Physician profile
Bruce Czarnik
NPI 1114974532
$3,411.14
in general payments reported to CMS, 2019-2025
23 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $228 · 2021: $222 · 2022: $591 · 2023: $435 · 2024: $599 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $978.35 | 2019-2023 | Quartet |
| Kestra Medical Technology Services, INC. | $346.49 | 2023-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $326.58 | 2022-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $194.86 | 2024 | Barostim Neo System |
| Boston Scientific Corporation | $193.63 | 2023-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Abiomed | $148.49 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $148.10 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $145.08 | 2020-2025 | Farxiga |
| Itamar Medical INC | $120.24 | 2023 | Watchpatone |
| Edwards Lifesciences Corporation | $115.41 | 2024 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $114.91 | 2019 | |
| Lantheus Medical Imaging, INC. | $85.76 | 2022-2025 | |
| Pfizer INC. | $73.63 | 2019-2025 | |
| Medtronic, INC. | $71.54 | 2024 | Micra, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.14 | 2021-2023 | Lifevest |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $54.90 | 2024 | Xarelto |
| Amgen INC. | $43.93 | 2019-2025 | Repatha, Repatha |
| Heartflow, INC. | $43.07 | 2025 | |
| Esperion Therapeutics, INC. | $40.20 | 2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $37.19 | 2022-2025 | |
| Astellas Pharma US INC | $22.57 | 2021 | |
| Philips North America LLC | $17.81 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Bayer Healthcare Pharmaceuticals INC. | $17.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Czarnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.